Pfizer Inc. announced today that the European Commission (EC) has
granted marketing authorization for INLYTA® (axitinib) for
the treatment of adult patients with advanced renal cell carcinoma
(RCC), a type of kidney cancer, after failure of prior treatment with
sunitinib or a cytokine.
INLYTA, a kinase inhibitor, is an oral therapy that was designed to
selectively inhibit vascular endothelial growth factor (VEGF) receptors
1, 2 and 3, which are proteins that can influence tumor
growth, vascular angiogenesis and progression of cancer (tumor spread).
"INLYTA offers physicians and their patients with advanced kidney cancer
a new treatment option following prior treatment with sunitinib or a
cytokine. INLYTA data demonstrate statistically significant improvement
in progression free survival compared with sorafenib, and support the
continued role for VEGFR-targeted therapy, following the first-line
standard of care, SUTENT," said Dr. Bernard Escudier, Head of the
Immunotherapy Unit, Department of Medical Oncology, Institut Gustave
Roussy, France, who served as an investigator on this Pfizer-sponsored
study and is a paid consultant to Pfizer Oncology.